Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus

Therapeutic Advances in Endocrinology and Metabolism

Volumn 6, Issue 2, 2015, Pages 61-67

  Liakos, Aris ^a   Karagiannis, Thomas ^a   Bekiari, Eleni ^a   Boura, Panagiota ^a   Tsapas, Apostolos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

BMS512148; cost effectiveness; dapagliflozin; Farxiga ; Forxiga ; sodium glucose cotransporter 2 (SGLT2); type 2 diabetes mellitus; Xigduo

Indexed keywords

DAPAGLIFLOZIN; GLIPIZIDE; HEMOGLOBIN A1C; PIOGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA;

BLOOD PRESSURE; BREAST CANCER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; META ANALYSIS (TOPIC); MILD RENAL IMPAIRMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84930580913     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018814560735     Document Type: Review

References (37)

1. AstraZeneca Pharmaceuticals and Bristol-Myers Squibb (2014) Highlights of prescribing information. Farxiga (dapagliflozin) tablets, for oral use. Princeton, NJ: Bristol-Myers Squibb Company. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
2. Baker W. Smyth L. Riche D. Bourret E. Chamberlin K. White W. (2014) Effects of sodium–glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8: 262–275.
3. Bolinder J. Ljunggren O. Kullberg J. Johansson L. Wilding J. Langkilde A. et al. (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97: 1020–1031.
4. Brennan A. Chick S. Davies R. (2006) A taxonomy of model structures for economic evaluation of health technologies. Health Econ 15: 1295–1310.
5. Clarke P. Gray A. Briggs A. Farmer A. Fenn P. Stevens R. et al. (2004) A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47: 1747–1759.
6. Elgart J. Prestes M. Gonzalez L. Aschner P. Garrido Lecca S. Aiello E. et al. (2014 a) PDB 56 – dapagliflozin versus sulfonylurea as an add-on therapy to metformin: a cost-effectiveness analysis in Colombia. Value Health 17: A247.
7. Elgart J. Prestes M. Gonzalez L. Asteazaran S. Aiello E. Garrido Lecca S. et al. (2014 b) PDB 63 – dapagliflozin: cost-effectiveness as an add-on therapy to metformin in the treatment of type 2 diabetes (T2DM) in Argentina and Chile. Value Health 17: A248.
8. European Medicines Agency (2012) Assessment report: Forxiga (Dapagliflozin). Procedure no. EMEA/H/C/002322. London: European Medicines Agency.
9. European Medicines Agency (2014 a) Forxiga® Summary of product characteristics. London: European Medicines Agency.
10. European Medicines Agency (2014 b) Xigduo® Summary of product characteristics. London: European Medicines Agency.
11. Fioretto P. Bruin T. Johnsson E. Ptaszynska A. Parikh S. List J. (2013) Safety and efficacy of the SGLT 2 inhibitor dapagliflozin in older patients with type 2 diabetes. Diabetologia 56: S383.
12. Garber A. Abrahamson M. Barzilay J. Blonde L. Bloomgarden Z. Bush M. et al. (2013) AACE comprehensive diabetes management algorithm 2013. Endocr Pract 19: 327–336.
13. Goring S. Hawkins N. Wygant G. Roudaut M. Townsend R. Wood I. et al. (2014) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 16: 433–442.
14. Institute for Quality and Efficiency in Health Care (2013) Dapagliflozin – benefit assessment according to § 35a Social Code Book V. Cologne, Germany: Institute for Quality and Efficiency in Health Care.
15. International Diabetes Federation (2013) IDF Diabetes Atlas, 6th edn. Brussels: International Diabetes Federation.
16. Inzucchi S. Bergenstal R. Buse J. Diamant M. Ferrannini E. Nauck M. et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364–1379.
17. Iqbal N. Weber M. Mansfield T. List J. Ptaszynska A. (2014) Dapagliflozin lowered ambulatory BP in patients with type 2 diabetes mellitus and hypertension inadequately controlled by a renin-angiotensin system blocker ± another agent. Diabetologia 57: S334.
18. Jabbour S. Hardy E. Sugg J. Parikh S. and for the Study 10 Group. (2014) Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37: 740–750.
19. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013) Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 473–478.
20. Kohan D. Fioretto P. Tang W. List J. (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85: 962–971.
21. Lambers Heerspink H. de Zeeuw D. Wie L. Leslie B. List J. (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15: 853–862.
22. Langkilde A. Nauck M. Prato S. Duran-Garcia S. Rohwedder K. Theuerkauf A. et al. (2013) Durability of dapagliflozin vs glipizide as add-on therapies in type 2 diabetes inadequately controlled on metformin: 4-year data. Diebetologia 56: S374.
23. List J. Woo V. Morales E. Tang W. Fiedorek F. (2009) Sodium–glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650–657.
24. National Institute for Health and Care Excellence (2013) Dapagliflozin in combination therapy for treating type 2 diabetes. London: National Institute for Health and Care Excellence.
25. Neslusan C. Teschemaker A. Martin S. Willis M. Johansen P. (2014) PDB 62 - Cost-effectiveness analysis of canagliflozin (CANA) versus dapagliflozin (DAPA) as an add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM) in the United States. Value Health 17: A248.
26. Oliver A. Mossialos E. Robinson R. (2004) Health technology assessment and its influence on health-care priority setting. Int J Technol Assess Health Care 20: 1–10.
27. Orme M. Fenici P. Lomon I. Wygant G. Townsend R. Roudaut M. (2014) A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetol Metab Syndr 6: 73.
28. Pharmaceutical Benefits Advisory Committee (2012 a) Public summary document: Dapagliflozin, tablet, 10 mg, (as propanediol monohydrate), Forxiga® (dual oral). Canberra: Australian Government, Department of Health, Pharmaceutical Benefits Advisory Committee.
29. Pharmaceutical Benefits Advisory Committee (2012 b) Public summary document: Dapagliflozin, tablet, 10 mg, (as propanediol monohydrate), Forxiga® (insulin). Canberra: Australian Government, Department of Health, Pharmaceutical Benefits Advisory Committee.
30. Pharmaceutical Benefits Advisory Committee (2013) Public summary document: Dapaglilfozin, tablet, 10 mg, Forxiga®. Canberra: Australian Government, Department of Health, Pharmaceutical Benefits Advisory Committee.
31. Rosenstock J. Vico M. Wei L. Salsali A. List J. (2012) Effects of dapagliflozin, an SGLT 2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35: 1473–1478.
32. Sabale U. Ekman M. Granstrom O. Bergenheim K. McEwan P. (2014) Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 16 May 2014. DOI: 10.1016/j.pcd.2014.04.007. [Epub ahead of print].
33. US Food and Drug Administration (2011) FDA briefing document. NDA 202293. Dapagliflozin tablets, 5 and 10 mg. Silver Spring, MD: US Food and Drug Administration.
34. US Food and Drug Administration (2013) FDA briefing document. NDA 202293. Dapagliflozin oral tablets, 5 and 10 mg. Silver Spring, MD: US Food and Drug Administration.
35. van Haalen H. Pompen M. Bergenheim K. McEwan P. Townsend R. Roudaut M. (2014) Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig 34: 135–146.
36. Vasilakou D. Karagiannis T. Athanasiadou E. Mainou M. Liakos A. Bekiari E. et al. (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159: 262–274.
37. Wilding J. Woo V. Rohwedder K. Sugg J. Parikh S. and for the Dapagliflozin 006 Study Group (2013) Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 16: 124–136.